What is Senzime?
Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors. Its flagship product, TetraGraph, digitally and continuously measures the degree of neuromuscular blockade in patients undergoing anesthesia. The system aims to enhance clinical precision and simplify healthcare management by preventing complications and guiding healthcare professionals in adhering to drug recommendations. This innovation is positioned to contribute to shorter hospital stays and reduced healthcare costs, aligning with a vision of a world free from anesthesia-related complications.
How much funding has Senzime raised?
Senzime has raised a total of $8.3M across 2 funding rounds:
Private Equity
$1.1M
Private Equity
$7.1M
Private Equity (2015): $1.2M, investors not publicly disclosed
Private Equity (2016): $7.1M, investors not publicly disclosed
What's next for Senzime?
The substantial enterprise-level funding and recent strategic investment indicate Senzime is poised for significant scaling and market penetration. This capital infusion will likely fuel further research and development, expansion of manufacturing capabilities, and broader commercialization efforts for the TetraGraph system. The company's focus on improving patient outcomes and reducing healthcare expenditures positions it favorably within the growing global market for patient monitoring solutions, which is valued in excess of SEK 15 billion in Europe and the United States.
See full Senzime company page
